Symbols

PRTA

Prothena·NASDAQ

--(--)

PRTA fundamentals

PRTA Q4 2025 Earnings

Prothena (PRTA) released its earnings on Feb 19, 2026: revenue was 21.00K (YoY -99.01%), missed estimates; EPS was -0.4 (YoY +62.96%), beat estimates.

Revenue / YoY

21.00K

-99.01%

EPS / YoY

-0.4

+62.96%

Report date

Feb 19, 2026

PRTA Earnings Call Summary for Q4,2025

Phase III Trials: Prasinezumab and coramitug in Phase III; BMS-986446 Phase II completion in 2027.
$105M Milestones: Potential 2026 payments from coramitug and PRX019.
CYTOPE Innovation: TDP-43 targeting in ALS; PRX012-TfR reduces ARIA-E risk.
Financial Resilience: $308.4M cash in 2025; 2026 ending cash of ~$255M.

Earnings

EPS

Revenue

Revenue & Expenses

PRTA has released its 2025 Q4 earnings report, with revenue of 21.00K, reflecting a YoY change of -99.01%, and net profit of -21.59M, showing a YoY change of 62.75%. The Sankey diagram below clearly presents PRTA's revenue sources and cost distribution.

Key Indicators

Prothena (PRTA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Prothena (PRTA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Prothena (PRTA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Prothena (PRTA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown